Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain
Xenon Pharmaceuticals (NASDAQ:XENE) has announced an upcoming investor webinar scheduled for October 6, 2025, focused on their early-stage programs targeting Kv7 and Nav1.7 as potential non-opioid treatments for pain.
The webinar, titled "Developing Novel Non-Opioid Treatments for Pain," will be held from 11:30 AM to 12:30 PM Eastern Time. Investors can submit questions during the live webinar via chat or in advance by email. The company's lead molecule, azetukalner, is currently in Phase 3 trials for epilepsy, major depressive disorder, and bipolar depression, while their pain treatment programs are in Phase 1 development.
Xenon Pharmaceuticals (NASDAQ:XENE) ha annunciato un prossimo webinar per investitori previsto per 6 ottobre 2025, incentrato sui programmi in fase iniziale che prendono di mira Kv7 e Nav1.7 come potenziali trattamenti non oppioidi per il dolore.
Il webinar, intitolato "Developing Novel Non-Opioid Treatments for Pain", si terrà dalle 11:30 alle 12:30 ora orientale. Gli investitori possono inviare domande durante il webinar in diretta tramite chat o in anticipo via email. Il composto principale dell'azienda, azetukalner, è attualmente in trial di fase 3 per epilessia, disturbo depressivo maggiore e depressione bipolare, mentre i programmi di trattamento del dolore sono in sviluppo di Fase 1.
Xenon Pharmaceuticals (NASDAQ:XENE) ha anunciado un próximo seminario web para inversionistas programado para el 6 de octubre de 2025, enfocado en sus programas en etapa temprana que apuntan a Kv7 y Nav1.7 como posibles tratamientos no opioides para el dolor.
El seminario, titulado "Developing Novel Non-Opioid Treatments for Pain", se llevará a cabo de 11:30 AM a 12:30 PM hora del Este. Los inversionistas pueden enviar preguntas durante el seminario en vivo vía chat o por correo electrónico con anticipación. El molécula principal de la compañía, azetukalner, se encuentra actualmente en ensayos de fase 3 para epilepsia, trastorno depresivo mayor y depresión bipolar, mientras que sus programas de tratamiento del dolor están en desarrollo en Fase 1.
Xenon Pharmaceuticals (NASDAQ:XENE)는 Kv7 및 Nav1.7를 겨냥한 초기 단계 프로그램에 초점을 맞춘 투자자 웨비나가 2025년 10월 6일에 예정되어 있다고 발표했습니다.
웨비나의 제목은 "Developing Novel Non-Opioid Treatments for Pain"이며 동부 표준시 기준 11:30 AM~12:30 PM에 진행됩니다. 투자자들은 라이브 웨비나 중 채팅으로 질문을 제출하거나 사전에 이메일로 제출할 수 있습니다. 회사의 선도 분자인 azetukalner은 현재 간질, 주요 우울 장애, 양극성 우울증에 대해 3상 시험 중이며, 통증 치료 프로그램은 1상 개발 중입니다.
Xenon Pharmaceuticals (NASDAQ:XENE) a annoncé un prochain webinaire pour investisseurs prévu le 6 octobre 2025, axé sur leurs programmes en phase précoce visant Kv7 et Nav1.7 comme traitements non opioïdes potentiels pour la douleur.
Le webinaire, intitulé "Developing Novel Non-Opioid Treatments for Pain", aura lieu de 11h30 à 12h30, heure de l'Est. Les investisseurs peuvent soumettre leurs questions pendant le webinaire en direct via le chat ou à l'avance par courriel. La molécule principale de l'entreprise, azetukalner, est actuellement en essais de phase 3 pour l'épilepsie, le trouble depressif majeur et la dépression bipolaire, tandis que leurs programmes de traitement de la douleur sont en développement de phase 1.
Xenon Pharmaceuticals (NASDAQ:XENE) hat einen bevorstehenden Investoren-Webinar angekündigt, das am 6. Oktober 2025 stattfinden wird und sich auf ihre Early-Stage-Programme konzentriert, die Kv7 und Nav1.7 als potenzielle nicht-opioide Behandlungen gegen Schmerzen anvisieren.
Das Webinar mit dem Titel "Developing Novel Non-Opioid Treatments for Pain" findet von 11:30 bis 12:30 Uhr Eastern Time statt. Investoren können während des Live-Webinars per Chat Fragen stellen oder im Voraus per E-Mail senden. Das führende Molekül des Unternehmens, azetukalner, befindet sich derzeit in Phase-3-Studien für Epilepsie, Major Depression und bipolare Depression, während die Schmerzbehandlungsprogramme sich in der Phase-1-Entwicklung befinden.
Xenon Pharmaceuticals (NASDAQ:XENE) أعلنت عن ويبِنار استثماري قادم مقرر في 6 أكتوبر 2025 يركّز على برامجها في المراحل المبكرة التي تستهدف Kv7 وNav1.7 كعلاجات محتملة للألم غير الأفيونية.
سيُعقد الويبِنار المعنونة "Developing Novel Non-Opioid Treatments for Pain" من 11:30 صباحاً حتى 12:30 ظهراً بتوقيت الساحل الشرقي. يمكن للمستثمرين تقديم أسئلة خلال الويبِنار المباشر عبر الدردشة أو مسبقاً عبر البريد الإلكتروني. الجزيء القيادي للشركة، azetukalner, حاليًا في تجارب المرحلة 3 للصرع، الاضطراب الاكتئابي الكبير، والاكتئاب ثنائي القطب، بينما برامج علاج الألم في التطوير من المرحلة 1.
Xenon Pharmaceuticals（NASDAQ:XENE）宣布将举办面向投资者的网络研讨会，定于2025年10月6日，聚焦其早期阶段的项目，针对 Kv7 和 Nav1.7，作为潜在的非阿片类止痛治疗。
研讨会题为"Developing Novel Non-Opioid Treatments for Pain"，将于东部时间上午11:30至12:30举行。投资者可在研讨会期间通过聊天实时提问，或提前通过电子邮件提交问题。公司的主力分子azetukalner目前正处于癫痫、重性抑郁障碍和双相抑郁障碍的三期试验，而其疼痛治疗计划处于第一阶段开发。
- None.
- None.
VANCOUVER, British Columbia and BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced that the company will host an investor webinar focused on its early-stage programs targeting Kv7 and Nav1.7 as potential non-opioid treatments for pain.
| Webinar: | Developing Novel Non-Opioid Treatments for Pain: An Overview of Xenon’s Nav1.7 and Kv7 Programs |
| Date: | Monday, October 6, 2025 |
| Time: | 11:30 AM – 12:30 PM Eastern Time |
| Webcast: | Register here |
| Format: | Questions may be submitted (via chat function) during the live webinar or submitted in advance via email to investors@xenon-pharma.com. |
A live webcast of the webinar will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed date and time are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contact:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
Media: media@xenon-pharma.com
Investors: investors@xenon-pharma.com
FAQ
When is Xenon Pharmaceuticals (XENE) hosting its investor webinar on pain treatment programs?
What early-stage programs will XENE discuss in the October 2025 webinar?
What is the current development stage of Xenon's (XENE) pain treatment programs?
What is the status of Xenon's (XENE) lead molecule azetukalner?
How can investors participate in Xenon's (XENE) October 2025 webinar?
